Navigation Links
Heart Disease Treatment Breakthrough
Date:6/1/2009

ycopene with milk and soy-based proteins to produce a much smaller, and more bio-available molecule. The early studies have shown that Ateronon can inhibit the oxidation of low density lipoprotein (LDL) cholesterol, which can put people at risk of suffereing heart attacks and stroke, to almost zero within eight weeks.

An estimated 17.5 million people died from heart and circulatory diseases in 2005, representing 30% of all global deaths. Of these deaths, an estimated 7.6 million were due to coronary heart disease and 5.7 million were due to stroke[1].

More than 117,000 people die each year in the UK from coronary heart disease. It accounts for one in five deaths in men and one in six deaths in women[2].

The four million people who take statins to help lower their cholesterol and chances of suffering a heart attack or stroke could benefit from using Ateronon. The product can be taken alongside statins.

Although cholesterol does put people at risk of suffering a heart attack or stroke, half of all heart attacks and three quarters of all strokes occur in people who do not have raised cholesterol.

Large scale studies of Ateronon are being undertaken at Addenbrookes Hospital, Cambridge, and at Harvard Medical School, in the expectation that they will demonstrate that the reduction of LDL oxidation is translated into improved heart and circulatory health - and improved survival rates.

The study was built on research originally carried out by the multi-national food giant Nestle, who were looking for a way to capture the therapeutic benefits of the tomato-derived compound lycopene.

After its launch to doctors this month, Ateronon will be made available direct to consumers through high street pharmacists from July onwards.

Dr Gunter Schmidt, a biologist and chief executive of CTL, said he was confident that once doctors had observed
'/>"/>

SOURCE Ateronon.com
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Many Heart Attack Patients Dont Get Best Emergency Treatment
2. The Heart, Diabetes, And Weight Loss Centers of New York Introduce the New Science of Metabolic Diagnosis and Weight Management
3. American Heart Association Comment Saving Lives in Type 2 Diabetics: Could It Be as Easy as Lowering Blood Pressure?
4. Terumo Heart to Announce Results of European Clinical Trial of DuraHeart(TM) LVAS at European Association of Cardiothoracic Surgeons Meeting in September
5. WorldHeart Announces Further Milestone in Miniaturized Assist Pump Development
6. CellCyte Genetics Corp. Enters Collaborative Research Agreement With Cleveland Clinic Foundation to Qualify Stem Cell Delivery in Damaged Heart Tissue
7. Its Only Heartburn...or is it? Chronic Heartburn a Risk Factor for Precursor to Esophageal Cancer
8. Cleveland Clinic Study Shows the Diabetes Drug Pioglitazone Reduces Risk of Death, Heart Attack and Stroke, but Increases Risk of Heart Failure
9. Hypertension: Journal of the American Heart Association Rapid Access Reports: Hispanics Hypertension Better Controlled With Equal Access to Care
10. Terumo Heart Reports Summary of DuraHeart(TM) LVAS Clinical Trial Results
11. ECLIPSE Data on Effects of Otsukas Investigational Novel Treatment, Tolvaptan, on Advanced Heart Failure Patients Hemodynamics and Urine Output Featured in Heart Failure Society of Americas Late Breaking Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... – Small Cap IR issues report. Recently, Arrayit Corporation ... blood card technology to Vivos, Global Genome Vault, the ... an impervious, impenetrable and permanent DNA storage vault, able ... Earth, a safe and secure nuclear blast-proof, underground shelter ... rapid collection, separation, drying and storage of human genomic ...
(Date:6/30/2015)... N.C. , June 30, 2015  Marken, the ... to the life sciences industry, has been granted permission ... patient shipment of clinical drug product in Korea.  This ... South Korea to continue receiving their clinical ... System (MERS). The emergency was caused by ...
(Date:6/30/2015)...  Isis Pharmaceuticals, Inc. (NASDAQ: ISIS ) announces ... of StockholdersWhen:Tuesday, June 30 at 5:10 p.m. ET / ... log onto our website listed above.   ... event, a replay of the webcast will be available ... ABOUT ISIS PHARMACEUTICALS, INC. Isis is ...
Breaking Medicine Technology:Small Cap IR - Empowering the Age of Genetic Enlightenment 2Marken Delivers Direct To Patients During MERS Outbreak 2Marken Delivers Direct To Patients During MERS Outbreak 3Webcast Alert: Corporate Presentation at the 2015 Isis Pharmaceuticals Annual Stockholder Meeting 2Webcast Alert: Corporate Presentation at the 2015 Isis Pharmaceuticals Annual Stockholder Meeting 3
... Feb. 23 MAP,Pharmaceuticals, Inc. (Nasdaq: ... 3 clinical trial of Unit Dose Budesonide (UDB) ... The Company announced that the clinical,trial did not ... by,changes from baseline in nighttime and daytime composite ...
... BCRX ) today announced that the full ... peramivir in patients hospitalized for influenza was presented by ... Professor, Divisions of Infectious Diseases and Organ Transplantation at ... the XI International Symposium on Respiratory Viral Infections taking ...
Cached Medicine Technology:MAP Pharmaceuticals Announces Phase 3 Study of Unit Dose Budesonide in Children With Asthma Did Not Meet Primary Endpoints 2MAP Pharmaceuticals Announces Phase 3 Study of Unit Dose Budesonide in Children With Asthma Did Not Meet Primary Endpoints 3Data from Phase 2 Study of Peramivir in Patients Hospitalized with Influenza Presented at the XI International Symposium on Respiratory Viral Infections 2Data from Phase 2 Study of Peramivir in Patients Hospitalized with Influenza Presented at the XI International Symposium on Respiratory Viral Infections 3Data from Phase 2 Study of Peramivir in Patients Hospitalized with Influenza Presented at the XI International Symposium on Respiratory Viral Infections 4Data from Phase 2 Study of Peramivir in Patients Hospitalized with Influenza Presented at the XI International Symposium on Respiratory Viral Infections 5
(Date:6/30/2015)... ... 30, 2015 , ... University Post-Acute Rehab recently released a ... rehab center’s patients and their experiences at the facility. Medicare granted University Post-Acute ... Each patient attests to the high rating, which is predominantly based on cleanliness, ...
(Date:6/30/2015)... ... 2015 , ... According to a June 15th report from USC ... sensory stimuli can be used to “decrease children’s anxiety and negative responses during oral ... will compare patient experience in a “typical dental environment” with one that provides “visual, ...
(Date:6/30/2015)... ... 30, 2015 , ... Broadway by the Sea posted its newest YouTube video ... testimonials. Medicare rated the care center as a five-star location based on a comprehensive ... future patients a firsthand look at the facility’s satisfied residents. , “In this ...
(Date:6/30/2015)... ... June 30, 2015 , ... After many requests from ... its here, http://www.express-glasses.com is proud to announce its collaboration with DHL ... shipping with DHL Express when calling or visiting the express glasses website. express ...
(Date:6/30/2015)... ... June 30, 2015 , ... The ... a federal multidistrict litigation now underway in the U.S. District Court, Eastern District ... Conference. According to the Court’s calendar, that conference has now been scheduled for ...
Breaking Medicine News(10 mins):Health News:Patients of University Post-Acute Rehab Support Five-Star Rating in New Video 2Health News:New Study Aims to Determine if Sensory Stimuli can Ease Dental Anxiety in Children, Notes Medical Center Dental Care 2Health News:New Study Aims to Determine if Sensory Stimuli can Ease Dental Anxiety in Children, Notes Medical Center Dental Care 3Health News:Broadway by the Sea Video Promotes Top Quality Service 2Health News:Eyeglasses Online - Express Glasses Announcing New International Shipping Using DHL 2Health News:Progress of Federal Xarelto Lawsuits Pending in Multidistrict Litigation to Be Discussed During July 9th Status Conference 2Health News:Progress of Federal Xarelto Lawsuits Pending in Multidistrict Litigation to Be Discussed During July 9th Status Conference 3
... November 2, 2008 at this year,s liver ... 4, SAN FRANCISCO, Oct. 28 The goal of ... Paul Angulo, was to determine the,effects of fatty liver disease ... is especially important as nonalcoholic fatty liver disease,(NAFLD) is the ...
... 28 CoLucid Pharmaceuticals, Inc., an,innovative biotechnology ... disorders, announced today that it has appointed ... In this position, Hogan will apply more,than ... and biopharmaceutical,industries to drive CoLucid,s business development ...
... WOBURN, Mass., Oct. 28 Galenea Corp.,today announced ... and its,academic collaborators that gives Galenea a license ... other related disorders. The license grants,Galenea the exclusive ... indole-based agonists., The licensed compounds have demonstrated ...
... Brain Injury Association (CALBIA), a non-profit membership ... those affected by brain injury, together with the ... representing individuals sustaining traumatic brain injury , ... nation’s most important professional medical/legal conferences dealing with ...
... hemoglobin A1c monitoring market is forecast to surpass $272 million by ... population. Other growth drivers include greater glucose control and product innovations ... ... Jose, CA (PRWEB) October 28, 2008 -- World Health Organization forecasts ...
... you,re an individual watching the stock market crash or ... in the journal Psychological Science, examines how ... their behavior more than young adults when under stress ... looked at how stress affects decision making, even though ...
Cached Medicine News:Health News:Severe Health Risks Follow Adults Who Were Diagnosed With Nonalcoholic Fatty Liver Disease as Children 2Health News:CoLucid Pharmaceuticals Names Linda Hogan VP of Business Development 2Health News:CoLucid Pharmaceuticals Names Linda Hogan VP of Business Development 3Health News:Galenea and Organix Announce Exclusive License Agreement for 5-HT2C Agonists for the Treatment of Obesity 2Health News:Galenea and Organix Announce Exclusive License Agreement for 5-HT2C Agonists for the Treatment of Obesity 3Health News:California Brain Injury Association and Scarlett Law Group Conduct Medical/Legal Conference on Traumatic Brain Injury November 21 - 23rd, 2008 2Health News:California Brain Injury Association and Scarlett Law Group Conduct Medical/Legal Conference on Traumatic Brain Injury November 21 - 23rd, 2008 3Health News:Global Hemoglobin A1c Monitoring Market to Touch $272 Million by 2012, According to New Report by Global Industry Analysts, Inc. 2Health News:Global Hemoglobin A1c Monitoring Market to Touch $272 Million by 2012, According to New Report by Global Industry Analysts, Inc. 3Health News:Stress affects older adults more than young adults 2
The adult blanket provides full coverage for patients of all sizes. The generous size and versatility of these blankets include extra material for the shoulders and feet. The foot drape also reduces ...
This revolutionary system combines the CSZ Head Wrap and Patient Vest for a non-invasive whole body hypothermia system. This method of cooling the patient allows for early treatment that is fast, cos...
The fabric is antistatic and non-linting and is both oil and water repellent.These superior blankets are an environmental friendly alternative to disposable blankets....
The Bair Hugger outpatient blanket makes it easy to give your patients the benefit of prewarming and enhance patient comfort during outpatient procedures....
Medicine Products: